HUP9903104A2 - Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása, alkalmazásuk és glicinantagonistaként ezeket tartalmazó gyógyszerkészítmények - Google Patents

Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása, alkalmazásuk és glicinantagonistaként ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9903104A2
HUP9903104A2 HU9903104A HUP9903104A HUP9903104A2 HU P9903104 A2 HUP9903104 A2 HU P9903104A2 HU 9903104 A HU9903104 A HU 9903104A HU P9903104 A HUP9903104 A HU P9903104A HU P9903104 A2 HUP9903104 A2 HU P9903104A2
Authority
HU
Hungary
Prior art keywords
pyridazino
quinoline
preparation
oxide derivatives
medicaments containing
Prior art date
Application number
HU9903104A
Other languages
English (en)
Inventor
Wojciech Danysz
Markus Gold
Ivars Kalvinsh
Cristopher Graham Raphael Parsons
Irene Piskunova
Eugene Rozhkov
Original Assignee
Merz + Co. Gmbh & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz + Co. Gmbh & Co. filed Critical Merz + Co. Gmbh & Co.
Publication of HUP9903104A2 publication Critical patent/HUP9903104A2/hu
Publication of HUP9903104A3 publication Critical patent/HUP9903104A3/hu
Publication of HU223780B1 publication Critical patent/HU223780B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Az (I) általánős képletű piridil-ftalazin-diőnők - a képletben R1 és R2 jelentése egymástól függetlenül hidrőgénatőm, halőgénatőm,metőxicsőpőrt vagy együtt metiléndiőxicsőpőrtőt képeznek - ésgyógyászatilag elfőgadható sóik glicinB-antagőnista aktivitássalrendelkeznek. Fenti aktivitásűk következtében glűtaminergneűrőtranszmisszió hibás működésével és excitőtőxicitással kapsőlatősneűrőlógiai rendellenességek leküzdésére alkalmazhatók emlősökben. ŕ
HU9903104A 1996-07-25 1997-07-25 Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása és ezeket tartalmazó glicin antagonista hatású gyógyszerkészítmények HU223780B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
PCT/EP1997/004057 WO1998004556A1 (en) 1996-07-25 1997-07-25 Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists

Publications (3)

Publication Number Publication Date
HUP9903104A2 true HUP9903104A2 (hu) 2000-03-28
HUP9903104A3 HUP9903104A3 (en) 2000-04-28
HU223780B1 HU223780B1 (hu) 2005-01-28

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903104A HU223780B1 (hu) 1996-07-25 1997-07-25 Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása és ezeket tartalmazó glicin antagonista hatású gyógyszerkészítmények

Country Status (31)

Country Link
US (1) US5776935A (hu)
EP (1) EP0931081B1 (hu)
JP (1) JP3595342B2 (hu)
KR (1) KR100598206B1 (hu)
CN (1) CN1093860C (hu)
AR (1) AR004158A1 (hu)
AT (1) ATE224894T1 (hu)
AU (1) AU719993B2 (hu)
BR (1) BR9710569A (hu)
CA (1) CA2261923C (hu)
CZ (1) CZ289293B6 (hu)
DE (1) DE69715893T2 (hu)
DK (1) DK0931081T3 (hu)
EA (1) EA001711B1 (hu)
ES (1) ES2180041T3 (hu)
FI (1) FI112946B (hu)
GE (1) GEP20022801B (hu)
HK (1) HK1020193A1 (hu)
HU (1) HU223780B1 (hu)
IL (1) IL128225A (hu)
LT (1) LT4591B (hu)
LV (1) LV12260B (hu)
NO (1) NO310820B1 (hu)
PL (1) PL189572B1 (hu)
PT (1) PT931081E (hu)
SI (1) SI9720048B (hu)
SK (1) SK283536B6 (hu)
TW (1) TW402605B (hu)
UA (1) UA63911C2 (hu)
WO (1) WO1998004556A1 (hu)
ZA (1) ZA976612B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
AU2002329799B2 (en) * 2001-08-20 2007-03-15 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
US7279184B2 (en) * 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex
US20060280790A1 (en) * 2005-04-08 2006-12-14 Ju Tzuchi R Pharmaceutical formulations
KR20100063087A (ko) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
AU4296997A (en) 1998-02-20
NO990306D0 (no) 1999-01-22
EP0931081B1 (en) 2002-09-25
JP2000515872A (ja) 2000-11-28
CN1228778A (zh) 1999-09-15
PL189572B1 (pl) 2005-08-31
NO310820B1 (no) 2001-09-03
BR9710569A (pt) 1999-08-17
NO990306L (no) 1999-03-15
SK10399A3 (en) 2000-01-18
WO1998004556A1 (en) 1998-02-05
DE69715893D1 (de) 2002-10-31
JP3595342B2 (ja) 2004-12-02
CA2261923A1 (en) 1998-02-05
EP0931081A1 (en) 1999-07-28
DE69715893T2 (de) 2003-01-30
DK0931081T3 (da) 2003-01-27
AU719993B2 (en) 2000-05-18
AR004158A1 (es) 1998-11-04
SI9720048B (sl) 2002-02-28
GEP20022801B (en) 2002-09-25
IL128225A0 (en) 1999-11-30
EA199900161A1 (ru) 1999-10-28
KR100598206B1 (ko) 2006-07-07
FI990134A0 (fi) 1999-01-25
LV12260A (lv) 1999-04-20
FI112946B (fi) 2004-02-13
CZ2019997A3 (cs) 1999-09-15
CZ289293B6 (cs) 2001-12-12
SK283536B6 (sk) 2003-09-11
ATE224894T1 (de) 2002-10-15
HU223780B1 (hu) 2005-01-28
HUP9903104A3 (en) 2000-04-28
PL331323A1 (en) 1999-07-05
ZA976612B (en) 1998-02-10
US5776935A (en) 1998-07-07
TW402605B (en) 2000-08-21
LT99007A (en) 1999-07-26
LV12260B (en) 1999-08-20
UA63911C2 (uk) 2004-02-16
PT931081E (pt) 2003-02-28
LT4591B (lt) 1999-12-27
HK1020193A1 (en) 2000-03-31
IL128225A (en) 2005-09-25
CA2261923C (en) 2006-01-24
EA001711B1 (ru) 2001-06-25
KR20000029568A (ko) 2000-05-25
SI9720048A (sl) 1999-12-31
ES2180041T3 (es) 2003-02-01
FI990134A (fi) 1999-03-24
CN1093860C (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
HUP9903104A2 (hu) Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása, alkalmazásuk és glicinantagonistaként ezeket tartalmazó gyógyszerkészítmények
IE781036L (en) Pyridopyrimidines
ATE38227T1 (de) Pharmakologisch aktive derivate von pyrido(1,5)benzodiazepinon.
ATE218567T1 (de) 1h-pyrido(3,4-b)indolcarboxamidderivate, ihre herstellung und therapeutische verwendung
NO163856C (no) Fremgangsmaate til fremstilling av ikke-toksiske salter av6-metyl-3,4-dihydro-1,2,3-oksatiazin-4-on-2,2-dioksyd.
NO20000605L (no) 3-Substituerte 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5]tieno[2,3- D]pyrimidinderivater, deres fremstilling og anvendelse som 5HT- antagonister
ATE49000T1 (de) Pyrido(1,2-a>pyrimidinderivate.
IL84916A0 (en) Tricyclic 1h-imidazole-5-carboxylic acid derivatives,their preparation and their use as herbicides
IE44989L (en) INDOLO [3,2,1-d,e] [1,5] NAPHTHYRIDINE DERIVATIVES
ATE41001T1 (de) Imidazo(1,2-a)chinoline, deren herstellung und deren therapeutische verwendung.
FI922874A (fi) Amonometyl-substiruerade 2,3-dihydropyrano/2,3-b/pyridiner, foerfarandefoer framstaellning av dessa och anvaendning av dessa i laekemedel
ES2046528T3 (es) Derivados heterotetraciclicos de lactamas, proceso para su preparacion y composiciones farmaceuticas a base de los mismos.
IT8025781A0 (it) Composizione farmaceutica per la somministrazione orale del metilestere dell'acido 13a-etil-2,3,5,6,12,13,13a,13b-ottaidro-12-idrossi1h-indolo-[3,2,1-de] pirido [3,2,1-ij] [1,5] naftiridina -12-carbossilico
GR3000930T3 (en) Pyrido (1,2-a) pyrimidine derivatives
AU7720587A (en) Substituted hexahydroarylquinolizines
IT1214756B (it) Derivati del 4h-benzo[4,5]cicloepta [1,2-b]tiofene,loro preparazione eloro impiego come medicamenti
DE3670843D1 (de) (9-substituiertes thio)-4h-pyrido(1,2-a)pyrimidin-4-onderivate, ihre herstellung und verwendung.
NO177786C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater
ES542583A0 (es) Procedimiento para la preparacion de nuevos derivados de triazolopirimidina.
NZ195324A (en) 2,3,5,6,11,11b-hexahydroimidazo(1',5':1,2)-or 1,2,3,4,6,7,12,12b-octahydropyrimido(1',6':1,2)pyrido(3,4-b)indole(1,3or 2,4)-diones
CA2113623A1 (en) Use of quinolizine derivatives as orexigenics
ATE64377T1 (de) Substituierte aminderivate, ihre herstellung und verwendung.
LV5622A3 (lv) Panemiens aizvietotu 1,3,4,9-tetrahidropirano(3,4-b)indol-1-il-etikskabju vai to farmaceitiski saderigu salu iegusanai
IT8640042A1 (it) Tampone da gettare dopo l'uso, per l'igiene intima femminile
IT8421648A1 (it) Nuove difluoroepossidoeritromicine, il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che contengono i nuovi prodotti

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20041207